
    
      OUTLINE: This is a multi-center study.

        -  Fludarabine 25 mg/m2 IV over 30 minutes , Days 1, 2, 4

        -  Velcade(given after fludarabine) 1.3 mg/m2 IV push over 3 to 5 seconds, Days 1, 4, 8, 11

        -  Rituximab (given after Velcade) 375 mg/m2 IV piggyback, Day 1

        -  Cycle = 28 days; max 6 cycles

      ECOG Performance Status: 0-2

      Life Expectancy: Not specified

      Hematopoietic:

        -  Absolute neutrophil count (ANC) ≥ 1.5 K/mm3 (ANC > 0.5 K/mm3 if known lymphomatous
           involvement of the bone marrow).

        -  Platelets ≥ 100 K/mm3 (Platelets >50 K/mm3 if known lymphomatous involvement of the bone
           marrow).

      Hepatic:

        -  Total bilirubin ≤1.5 ULN

        -  Aspartate aminotransferase (AST, SGOT) ≤ 2.5 x ULN

        -  Alanine aminotransferase (ALT, SGPT) ≤ 2.5 x ULN

      Renal:

        -  Creatinine < 1.5 x institutional upper limit (ULN) or creatinine clearance ≥ 50 cc/min

      Cardiovascular:

        -  No myocardial infarction within 6 months prior to enrollment

        -  No heart failure per New York Heart Association Classification III or IV

        -  No severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of
           acute ischemia
    
  